Zhengzhou Granlen PharmaTech

Zhengzhou Granlen PharmaTech is a chemistry-focused Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) headquartered in Zhengzhou, China. Founded in 2007 by Dr. Haoyun (Harry) An, the company provides a comprehensive range of drug discovery and development services to the global pharmaceutical and biotech industries. Their core expertise lies in medicinal chemistry, custom synthesis, process research and development, and the production of high-quality building blocks and intermediates. Granlen supports clients from early-stage lead generation and optimization through to the scale-up and manufacturing of active pharmaceutical ingredients (APIs). The company is particularly recognized for its technical proficiency in complex small molecule chemistry, including nucleoside and heterocyclic chemistry.